Financial loss constrains Richter Q3 profit growth
Hungarian pharmaceutical company Gedeon Richterʼs third-quarter net income edged up 2% year-on-year to HUF 22.6 billion, well under revenue growth as a financial loss weighed, Hungarian news agency MTI reports, citing an earnings report released before the opening bell on Friday.
Revenue climbed 8% to HUF 137.7 bln, supported by the success of Richterʼs anti-psychotic cariprazine. Direct cost of sales rose just 3% to HUF 59.4 bln, lifting gross profit 12% to HUF 78.3 bln.
Operating profit jumped 69% to HUF 30 bln, helped by a decline in sales and marketing costs, but the bottom line was hit by a HUF 4.5 bln financial loss, compared to a HUF 8.5 bln financial gain in the base period.
Improved margins lift Q1-Q3 profit
For the period Q1-Q3, Richterʼs net income rose 35% to HUF 83.1 bln.
Revenue climbed 13% to HUF 416.4 bln, outpacing the increase in direct costs of sales which rose 9% to HUF 175.6 bln.
Gross profit increased 16% to HUF 240.8 bln and operating profit jumped 58% to HUF 82.3 bln as sales and marketing expenses fell.
Richter noted that limitations on contact between sales reps and physicians due to the pandemic still impact promotional activities negatively.
A geographical breakdown of sales shows the United States was Richterʼs biggest market in Q1-Q3, bumping Russia out of the top spot. Turnover in the US climbed 64% to HUF 80.5 bln, lifted by sales of cariprazine, marketed there under the brand name Vraylar.
Sales in Russia edged up 1% to HUF 63.6 bln.
Domestic sales increased 3% to HUF 29.8 bln.
Oral contraceptives remained Richterʼs biggest seller in Q1-Q3, as sales rose 18% to HUF 83.5 bln. Cariprazine was runner-up as turnover jumped 73% to HUF 67.2 bln.
Policymakers Cut Central Bank Base Rate by 50 bp to 7.75%
Bulgaria's Household Income, Spending Rise 20% in 2023
Spar Magyarország Revenue Climbs Close to 16% in 2023
Hungary Launches HUF 15 bln Tourism Sector Support Program
SUPPORT THE BUDAPEST BUSINESS JOURNAL
Producing journalism that is worthy of the name is a costly business. For 27 years, the publishers, editors and reporters of the Budapest Business Journal have striven to bring you business news that works, information that you can trust, that is factual, accurate and presented without fear or favor.
Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.
